Notes
The study was funded by Bioverativ, a Sanofi Company, and Swedish Orphan Biovitrum AB.
Reference
Li N, et al. Cost-Effectiveness Analysis of rFVIIIFc, PEGylated rFVIII, and Emicizumab for the Prophylactic Treatment of Severe Hemophilia A Patients Without Inhibitors in the United States. 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus oral presentation) abstr. RO4, 18 May 2019. Available from: URL: https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2019/program
Rights and permissions
About this article
Cite this article
Recombinant factor VIII-Fc good choice in haemophilia A. PharmacoEcon Outcomes News 830, 28 (2019). https://doi.org/10.1007/s40274-019-5979-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5979-2